Lab
Mclaren Health Management Group
Mclaren Health Management Group was paid $1.75M by Medicaid between Jan 2018 and Dec 2024, across 156 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 14% of everything it billed.
33Billing provider infoMCLAREN HEALTH MANAGEMENT GROUP
FLINT, MI 48507
FLINT, MI 48507
33aNPI1477938686assigned 07/29/2015
33bProvider typeClinical Medical Laboratory
28Total paid$1.75M
24GClaims210,707
24DCodes billed156
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Michigan
Rank by total paid#28 of 108
Median peer was paid$588K
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LOY, STEVEN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 874 | $12K | |
| 2019 | 22,389 | $114K | |
| 2020 | 30,607 | $273K | |
| 2021 | 47,636 | $412K | |
| 2022 | 41,881 | $393K | |
| 2023 | 35,970 | $320K | |
| 2024incomplete | 31,350 | $228K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 14% | 15,249 | 10,285 | $241K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.8% | 7,062 | 6,979 | $102K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5.6% | 7,301 | 7,282 | $97K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.4% | 6,386 | 6,310 | $95K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.8% | 9,828 | 9,782 | $84K |
| 83013 | 4.5% | 1,899 | 1,894 | $80K | |
| 80053 | Comprehensive metabolic panel | 4.4% | 14,164 | 13,411 | $77K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.8% | 16,028 | 14,328 | $66K |
| 80061 | Lipid panel | 3.8% | 10,938 | 10,901 | $66K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.7% | 9,228 | 9,186 | $47K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.6% | 2,798 | 2,794 | $45K |
| 80074 | 2.3% | 1,864 | 1,841 | $41K |
144 more codes
| 84439 | 2.0% | 7,080 | $35K | |
| 82607 | 2.0% | 4,295 | $35K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.0% | 2,634 | $35K |
| 87390 | 1.9% | 3,143 | $34K | |
| 88307 | 1.8% | 268 | $32K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 8,972 | $30K |
| 87070 | 1.3% | 5,897 | $23K | |
| 88312 | 1.2% | 1,167 | $21K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 370 | $20K |
| 86702 | 1.1% | 3,182 | $20K | |
| 86696 | 1.0% | 1,762 | $18K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,484 | $16K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 562 | $15K |
| 86701 | <1% | 3,169 | $15K | |
| 87480 | <1% | 2,006 | $15K | |
| 87077 | <1% | 3,151 | $14K | |
| 87660 | <1% | 1,940 | $14K | |
| 87510 | <1% | 1,941 | $14K | |
| 86803 | <1% | 1,968 | $13K | |
| 87186 | <1% | 3,288 | $13K | |
| 86235 | <1% | 399 | $13K | |
| 86695 | <1% | 1,710 | $13K | |
| 88304 | <1% | 1,518 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,546 | $12K |
| 84154 | <1% | 1,119 | $12K | |
| 84481 | <1% | 1,923 | $12K | |
| 86003 | <1% | 206 | $11K | |
| 86038 | <1% | 1,628 | $10K | |
| 83655 | <1% | 1,225 | $8K | |
| 86200 | <1% | 863 | $7K | |
| 86694 | <1% | 913 | $7K | |
| 82105 | <1% | 671 | $7K | |
| 82746 | <1% | 881 | $6K | |
| 86480 | <1% | 223 | $6K | |
| 82043 | <1% | 1,665 | $6K | |
| 86376 | <1% | 665 | $6K | |
| 82570 | <1% | 1,713 | $6K | |
| 84144 | <1% | 385 | $5K | |
| 83014 | <1% | 900 | $5K | |
| 84153 | <1% | 539 | $5K | |
| 82728 | <1% | 672 | $4K | |
| 84702 | <1% | 584 | $4K | |
| 84165 | <1% | 422 | $4K | |
| 84403 | <1% | 237 | $3K | |
| 86780 | <1% | 555 | $3K | |
| 82248 | <1% | 1,854 | $3K | |
| 86592 | <1% | 1,627 | $3K | |
| 86706 | <1% | 723 | $3K | |
| 83735 | <1% | 950 | $3K | |
| 84146 | <1% | 267 | $3K | |
| 85027 | <1% | 800 | $3K | |
| 87340 | <1% | 698 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 161 | $3K |
| 83540 | <1% | 856 | $3K | |
| 83721 | <1% | 378 | $2K | |
| 86334 | <1% | 227 | $2K | |
| 86140 | <1% | 1,264 | $2K | |
| 82627 | <1% | 155 | $2K | |
| 83550 | <1% | 513 | $2K | |
| 84425 | <1% | 200 | $2K | |
| 87147 | <1% | 837 | $2K | |
| 80164 | <1% | 304 | $2K | |
| 86300 | <1% | 190 | $2K | |
| 83718 | <1% | 343 | $2K | |
| 84450 | <1% | 589 | $2K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 37 | $2K |
| 87205 | <1% | 862 | $2K | |
| 83525 | <1% | 296 | $2K | |
| 82626 | <1% | 163 | $2K | |
| 82085 | <1% | 365 | $2K | |
| 86225 | <1% | 179 | $2K | |
| 84460 | <1% | 606 | $1K | |
| 81003 | <1% | 1,032 | $1K | |
| 81001 | <1% | 900 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 125 | $1K |
| 87634 | <1% | 31 | $1K | |
| 83001 | <1% | 84 | $1K | |
| 88342 | <1% | 53 | $1K | |
| 82785 | <1% | 105 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 53 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,294 | $967.50 |
| 86258 | <1% | 57 | $913.84 | |
| 88142 | <1% | 103 | $910.11 | |
| 86364 | <1% | 57 | $884.22 | |
| 83002 | <1% | 69 | $878.38 | |
| 85652 | <1% | 1,034 | $856.00 | |
| 83690 | <1% | 227 | $845.59 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 18 | $831.81 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 48 | $826.50 |
| 82550 | <1% | 216 | $790.69 | |
| 86800 | <1% | 76 | $745.08 | |
| 83970 | <1% | 45 | $744.52 | |
| 84402 | <1% | 42 | $739.50 | |
| 82150 | <1% | 170 | $696.85 | |
| 84479 | <1% | 203 | $649.56 | |
| 82784 | <1% | 32 | $621.54 | |
| 84100 | <1% | 240 | $548.51 | |
| 82565 | <1% | 399 | $544.94 | |
| 86769 | <1% | 20 | $505.77 | |
| 82465 | <1% | 171 | $502.91 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 19 | $500.87 |
| 80177 | <1% | 43 | $404.25 | |
| 87075 | <1% | 88 | $385.37 | |
| 84550 | <1% | 183 | $382.12 | |
| 82274 | <1% | 34 | $347.94 | |
| 87081 | <1% | 170 | $345.04 | |
| 86160 | <1% | 21 | $336.34 | |
| 86141 | <1% | 38 | $330.98 | |
| 86762 | <1% | 67 | $327.42 | |
| 80076 | <1% | 96 | $309.55 | |
| 84520 | <1% | 257 | $291.49 | |
| 84703 | <1% | 59 | $278.21 | |
| 86431 | <1% | 85 | $254.37 | |
| 83516 | <1% | 30 | $250.11 | |
| 87427 | <1% | 41 | $243.88 | |
| 82670 | <1% | 14 | $241.64 | |
| 86708 | <1% | 45 | $227.21 | |
| 85660 | <1% | 58 | $207.77 | |
| 87045 | <1% | 43 | $198.54 | |
| 85060 | <1% | 13 | $182.91 | |
| 87338 | <1% | 16 | $170.43 | |
| 87209 | <1% | 14 | $146.34 | |
| 82330 | <1% | 20 | $134.09 | |
| 86704 | <1% | 28 | $133.56 | |
| 86709 | <1% | 35 | $124.69 | |
| 83020 | <1% | 12 | $123.60 | |
| 84166 | <1% | 12 | $123.60 | |
| 84207 | <1% | 24 | $113.09 | |
| 86787 | <1% | 14 | $107.46 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 12 | $96.86 |
| 80178 | <1% | 27 | $96.41 | |
| 82270 | <1% | 57 | $91.38 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14 | $91.30 |
| 86340 | <1% | 24 | $86.82 | |
| 86901 | <1% | 39 | $74.88 | |
| 86900 | <1% | 38 | $72.92 | |
| 87177 | <1% | 27 | $26.86 | |
| 84156 | <1% | 13 | $21.98 | |
| 87902 | <1% | 16 | $16.00 | |
| 82947 | <1% | 12 | $7.31 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 28 | $0.52 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 188 | $0.00 |
| 80050 | General health panel | 0% | 85 | $0.00 |
| 84480 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLOY, STEVEN (VP - CFO)
| Provider | Location | Paid |
|---|---|---|
| Mclaren Health Management Group | Clinton Twp, MI | $3.60M |
| Mclaren Health Management Group | Davison, MI | $2.53M |
| Mclaren Health Management Group | Bay City, MI | $1.86M |
| Mclaren Health Management Group | Davison, MI | $1.61M |
| Mclaren Health Management Group | Cheboygan, MI | $1.58M |
| Mclaren Health Management Group | Lansing, MI | $1.52M |
| Mclaren Health Management Group | Mt Pleasant, MI | $840K |
| Mclaren Health Management Group | Davison, MI | $720K |
| Mclaren Health Management Group | Davison, MI | $63K |
| Mclaren Health Management Group | Port Huron, MI | $56K |
| Mclaren Health Management Group | Fenton, MI | $48K |
| Mclaren Health Management Group | Davison, MI | $34K |
| Mclaren Health Management Group | Bad Axe, MI | $13K |
| Mclaren Health Management Group | Petoskey, MI | $8K |
| Mclaren Health Management Group | Lansing, MI | $7K |
| Mclaren Health Management Group | Mount Pleasant, MI | $5K |
| Mclaren Health Management Group | Petoskey, MI | $4K |
| Mclaren Health Management Group | Midland, MI | $3K |
| Mclaren Health Management Group | Davison, MI | $3K |
| Mclaren Health Management Group | Okemos, MI | $715.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.